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 ABSTRACT 
 
 
 
 Vaccines protect millions of human lives per year from otherwise fatal illnesses. 
Vaccination promotes immunity by simulating infection with a non-pathogenic 
representative of the disease, an antigen, to prepare and train an immune response. 
Vaccine-safe antigens are often too small to elicit an immune response. These non-
immunogenic molecules are referred to as haptens and are introduced to the immune 
system by hapten-carriers, large immune-stimulating proteins. Keyhole Limpet 
Hemocyanin (KLH), a respiratory protein of the giant keyhole limpet (Megathura 
crenulata), is the industry standard hapten-carrier. KLH is a potent yet safe immune-
stimulant relied upon in research, available human medications, and emerging vaccines. 
KLH is currently valued at approximately $10,000 per gram, and economic analysis 
predicts the KLH market to exceed $35 million once new vaccines are approved. KLH 
production, however, is neither ecologically sustainable nor economically sensible. KLH 
is produced from live M. crenulata and cannot be synthesized. Over-fishing endangers wild 
M. crenulata populations, and only one company is authorized to aquaculture this species. 
A potential alternative hapten-carrier is the hemocyanin from the red abalone (Haliotis 
rufescenes). Aquaculture for this species is well established and globally profitable; their 
meat is considered a delicacy, and their shell is the source of the gem ‘Mother of Pearl’. 
Red abalone hemocyanin (RAH) is biochemically similar to KLH. This study adapts KLH 
purification techniques to RAH for comparison. KLH and RAH were determined to be 
approximately the same molecular weight, a critical characteristic for an alternative hapten-
carrier. RAH isolation was optimized to rival commercial KLH purity. RAH, like KLH, 
 consists of two subunits between 350 kDa and 400 kDa. RAH elicits an antibody 
production response to conjugated haptens in mice. RAH is therefore a viable alternative 
to KLH as a hapten-carrier in vaccine production. There is precedent for abalone 
aquaculture in Maine. 
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INTRODUCTION 
 
 
 
Background 
 Vaccines prevent millions of deaths each year from once-common and fatal 
diseases (1). Vaccination promotes immunity by preparing and training the immune system 
to recognize and eliminate pathogens, harmful germs and viruses (1). Surface molecules 
called antigens are specific to each pathogen species, allowing the immune system to 
identify and attack the pathogen (2). Antigen detection triggers the immune system to 
produce antibodies, molecules that are designed to neutralize specific pathogens (3). 
Antibodies bind to their counterpart antigens to inhibit their harmful effects or mark the 
pathogen for destruction. (1). Antibodies are produced for each new pathogen encountered, 
and the host develops immunity to an illness once antibodies have been produced against 
antigens of the disease-causing pathogen (4).  
 It is important, however, that immunization does not result in infection. A 
successful and safe vaccine helps the immune system prepare antibodies against the 
pathogen without the patient becoming sick (1). Vaccines, therefore, typically introduce 
modified antigens that represent the pathogen to the immune system (1). Many antigens 
that are manipulated for vaccine safety are haptens, molecules too small to elicit an immune 
response (2). If the immune system cannot detect the hapten, antibody production will not 
occur, and immunity will never develop (1).  
 It is often necessary to deliver these haptens to the immune system in a recognizable 
form. Haptens are typically conjugated, or chemically attached, to large immune-
stimulating proteins called hapten-carriers (5). Hapten-carriers are coated in the hapten and 
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introduced to the host intravenously (6). Immune system cells are activated to investigate 
the large foreign hapten-carrier and discover the haptens on its surface (7). These haptens 
are thereby effectively presented to the immune system and immunization can progress (5). 
Successful hapten-carriers are large, high-molecular-weight, and phylogenetically distant 
proteins that cause no harm to the host (3). Hapten-carriers are often used in conjunction 
with adjuvants, substances that modify the immune response complementary to an antigen 
to accelerate immunity development and extend protection duration (8). This may result in 
general upregulation of components of the immune response, such as antibody production, 
or modulation of the way immune system cell types interact (1). 
 The most efficient hapten-carrier and adjuvant in research and medicine is the 
oxygen carrying protein from a Californian sea snail, the giant keyhole limpet (Megathura 
crenulata) (2). Keyhole Limpet Hemocyanin (KLH), a respiratory protein serving 
comparable functions to hemoglobin in human blood, from this limpet is the industry 
standard for immunological research and vaccine production (2).  KLH was discovered to 
be a potent, yet safe, immune stimulant in the 1950s (8). A single injection of KLH triggers 
intense immune system stimulation in nearly all vertebrates, including humans (8). KLH 
safely elicits both cellular and humoral immune responses in mammals and has thus been 
used in various immunological applications (5). By 1967 KLH was a standard for 
evaluating patient immunocompetence, or normal immune response efficacy (8). KLH is 
still used extensively in immunocompetence research and evaluation (2). Many antibody 
producers, businesses that prepare and supply antibodies to specific pathogens, prefer or 
require KLH as the hapten-carrier or complimentary adjuvant (2).  
 3 
 
 New immunotherapies use KLH as a hapten-carrier and adjuvant to bolster the 
patient immune system and treat existing illnesses (7). While preventative vaccines protect 
the patient from new sicknesses, immunotherapies and therapeutic vaccines treat present 
conditions (4). As an example, therapeutic vaccines use KLH to help the immune system 
recognize cancer cells as harmful (3). Immunotherapies are a rapidly growing 
pharmaceutical sector because of their ability to leverage natural immunological processes 
to fight current diseases that are not ordinarily recognized by the immune system (6).  
 KLH is also an immunotoxicology standard in monitoring the immune-suppressive 
side effects of candidate molecules for new drugs (7). Some diagnostic techniques for 
identifying illegal drugs and parasites in patients regularly utilize KLH (2). Beyond 
research products, KLH is used as a hapten-carrier in Immucothel, a leading bladder 
carcinoma treatment (9).  
 KLH has been used extensively as a multi-purpose immune-stimulant in clinical 
trials for decades but has recently garnered attention as a more efficient hapten-carrier in a 
variety of existing and emerging vaccines (9). There are approximately 20 different 
vaccines in late-stage clinical trials using KLH (10). These include preventative and 
therapeutic vaccines for illnesses such as Alzheimer’s, HIV/AIDS, Chron’s Disease, and a 
variety of cancers (10). Most of these KLH-incorporating vaccines are anticipated to enter 
the market in the next 3 years (11). KLH is currently valued at approximately $10,000 per 
gram, while economic analysis predicts the KLH market to exceed $35 million once the 
various vaccines are approved (10, 11). KLH production, however, cannot supply the 
growing demand (12). 
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 KLH is produced from the hemolymph (blood) of live M. crenulata and cannot be 
synthesized (12). One company, Stellar Biotechnologies Inc., has monopolized M. 
crenulata aquaculture, creating a bottleneck in pharmaceutical availability (12). This 
company sets the price and pace of most KLH research, restricting access for scientists and 
patients (12). Other businesses have already overfished the giant keyhole limpet for KLH 
used in research and available therapies, endangering the species (12). The wild population 
cannot support the imminent pressure of increased demand for KLH in emerging vaccines 
(12). Stellar Biotechnologies Inc. openly warns of their limited capacity to supply KLH for 
the new vaccines in their 2017 Financial Report (12). Stellar Biotechnologies Inc. is 
sustained mainly by grants and shareholders (12). Failure to attract investment will cripple 
their manufacturing capability (12). KLH production is therefore neither ecologically 
sustainable nor economically sensible. An alternative hapten-carrier is needed for the 
future of vaccine development. 
 Abalones and limpets are taxonomically related species. (13). Though abalones are 
in the Haliotidae family and M. crenulata is in the Fissurellidae family, both are 
vetigastropods, and the two types of sea snails share many characteristics (14). The 
hemocyanin of abalones has thus been investigated by immunologists as an alternative 
hapten-carrier to KLH in vaccine production and other immunological applications (14). 
The hemocyanins of various abalone species have been shown to be biochemically 
comparable to KLH (13). Importantly, the hemocyanin of most abalone species is 
approximately the same size, weight, and shape as KLH (15). These are critical 
characteristics for a successful alternative hapten-carrier (15). The carbohydrate 
composition, an important factor in hapten conjugation, of KLH and abalone hemocyanin 
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are also similar (16). Finally, abalone hemocyanin subunits may be more stable than KLH 
subunits after purification (14).  
 Hemocyanin from the red abalone (Haliotis rufescenes) has not been previously 
studied for use as a hapten-carrier. If H. rufescenes hemocyanin, which I refer to as RAH, 
is biochemically comparable to KLH, it may be a viable alternative hapten-carrier in 
vaccine production. The essential criteria are similarities of protein subunit size, shape, and 
weight (4). A competitive alternative hapten-carrier to KLH should be able to be extracted, 
isolated, and purified with comparable efficiency. Hapten carrying efficacy can be directly 
compared by conjugating the same hapten to both hemocyanins and testing their respective 
antibody production when injected into mice. Comparison of the respective antibody 
production against the hapten with the two hemocyanins will show if RAH is as effective 
as KLH. This study addresses the biochemical characteristics necessary to develop RAH 
as a KLH substitute, such as protein size. Maine is positioned to capitalize on abalone 
aquaculture for a variety of products, including RAH (17). Each abalone can be processed 
in a way that maximizes market diversity and minimizes waste– a sustainable advantage. 
 
Objectives 
1. To determine the requirements for sustained aquaculture of H. rufescenes.  
2. To adapt KLH extraction, isolation, and purification techniques to RAH.  
3. To compare the subunit structure and molecular weight of KLH and RAH.  
4. To assess overt effects of hemolymph extraction on abalone health.  
5. To determine the normal concentration of hemocyanin in H. rufescenes 
hemolymph.  
6. To conjugate a hapten to both KLH and RAH.  
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7. To raise antibodies against the given hapten in mice and assess respective antibody 
production using KLH and RAH as hapten-carriers. 
 
Appendix Guide 
 KLH and abalone hemocyanin structure and characteristics are discussed in 
Appendix A: KLH and Abalone Hemocyanin Biochemistry. Information pertaining to the 
differences in limpet and abalone harvest are discussed in Appendix B: Comparative 
Fishery Considerations. The economic landscape of KLH and various abalone products are 
discussed in Appendix C: Market Evaluation of Limpet and Abalone Products. 
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METHODS 
 
 
 
Abalone Maintenance 
 Seven red abalones were supplied from a previous behavioral study at the 
University of Maine Aquaculture Research Center (ARC) in 2014. These abalones were 
originally from The Abalone Farm (Cayucos, CA) and were 4 years when incorporated 
into the present study. The previous research did not affect the health of these abalones. 
Thirty-five more red abalones were supplied from The Abalone Farm (Cayucos, CA) in 
2015. These abalone were 2 years old at the time. All permits were filed and processed 
through the Aquaculture Research Institute (ARI) and the Maine Department of Marine 
Resources (DMR). The farm-raised abalones were originally grown in water directly from 
their natural California habitat and were fed a mixed diet of natural and processed feed 
prior to delivery at ARC for experimentation. 
 All abalones, once brought to ARC, were housed in approximately 150 gallons of 
artificial saltwater in ARC. The water was prepared using Crystal Sea Marine Mix. The 
primary housing enclosure was 2 meters long, 0.5 meters wide, and 0.65 meters deep. The 
waterflow rate was typically 2 liters per minute. Salinity was maintained at 34-38 ppt, while 
the water temperature range was 8oC to 14oC (typically 11oC), depending on air 
temperature and water-chiller-system settings. These are normal temperatures and 
salinities for wild H. rufescenes. Water quality was monitored for concentrations of 
ammonia, nitrate, nitrite, phosphorus, calcium. Dissolved oxygen and pH levels were also 
monitored. Tank water exceeding 0.5 ppm phosphate, 0.5 ppm ammonium, 0.5 ppm nitrate, 
and 10 ppm nitrate was treated with a 50% water-change. Ambient light over the enclosure 
was programmed for 12 hour light cycle per day.  
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 The abalones were originally fed “Abalone Broodstock Diet” from Adam and 
Amos Abalone Foods PTY LTD in Adelaide, Australia. Originally the abalones were fed 
a ‘chip’ formulation of this feed; this was switched to a ‘pellet’ formulation starting in 
2016. Abalone were also occasionally fed nori, a dried seaweed. All abalones were fed 3 
times a week, typically on Mondays, Wednesdays, and Fridays. Feed was not limited, and 
about 50 grams of food material were added to the tank each session. Each feeding began 
with a 25% tank water change to remove excess food. The variable nature of ARC systems 
resulted in occasional deviations from these parameters. 
 
Hemolymph Extraction 
 Commercial KLH production often extracts the total hemolymph volume from the 
limpets resulting in death. Scientists at Stellar Biotechnologies Inc., however, published 
descriptions of non-lethal extraction techniques for limpet and abalone hemolymph (12). 
This information was integrated with a protocol designed by Erin E. Switzer, a 2013 
University of Maine graduate student who studied abalone in the Bricknell Lab, and my 
previous experience with extracting hemolymph from horseshoe crabs (Limulus 
polyphemus) (18).  
 Large and active abalones were selected for hemocyanin extraction in advance. A 
selected individual was removed from the tank by sliding a flat object between its muscular 
foot and the aquarium wall and prying it upwards. The individual was then placed into an 
ice bath for 3 minutes. This slows the abalones, so they do not squirm during hemolymph 
extraction. The specimen is then held upside down in one hand, and a sanitary wipe was 
used to clean its foot.  
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 A sterile 22-gauge needle attached to a 1 mL syringe was then carefully inserted 
into the pedal sinus, a major hemolymph cavity (18). The pedal sinus is located just below 
the anterior edge of the foot, where there are two visible lobes (18). The needle is inserted 
less than a centimeter into this area of the foot, at a 45-degree angle with the front of the 
animal, to reach the pedal sinus.  
 A 1 mL sample of hemolymph was extracted at a time and added to a sterile 
Eppendorf tube on ice, for a total of 2 mL. Each animal experienced one to five attempts 
per bleeding until a total 2 mL of hemolymph was obtained. Specimens were returned to 
the tank after providing 2 mL of hemolymph or by the fifth attempt. The animals that were 
bled were monitored for changes in behavior for the duration of the study. Ten abalone 
were bled during this study, four of which were bled on two separate occasions. Nitrile 
gloves were worn throughout these processes to prevent sample contamination. Each 2 mL 
sample was separated into three 600 uL sub-samples for all subsequent experiments.  
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Hemocyanin Isolation 
 Initially the extracted raw hemolymph was added to Eppendorf tubes on ice that 
contained a marine anticoagulant (2.63 g sodium chloride, 1.8 g glucose, 0.088 g tris-
sodium citrate, 0.055 g citric acid, and 0.029 g EGTA per 100 milliliters of nanopore 
water). As the experiment progressed this marine anticoagulant was found to provide no 
advantage during the process and was removed from the protocol. Extracted raw 
hemolymph was then added to empty Eppendorf tubes on ice.  
 All hemolymph samples were subject to 30 minutes of 800 g centrifugation at 4oC 
immediately after collection. This was to prepare cell-free hemolymph; large particulates 
such as whole cells and contaminants were centrifuged down into the pellet at the bottom 
Figure 1. Diagram of abalone anatomy, dorsal view 
omitting shell. The site of hemolymph extraction, the 
pedal sinus, encircled in black, is located through the 
ventral surface of the foot. Circulatory system 
channels are shown in color. Image compiled from: 
https://ir.canterbury.ac.nz/handle/10092/1753 and 
http://content.cdlib.org/view?docId=kt738nb1zx&&d
oc.view=entire_text. 
Figure 2. Some of the red abalone (Haliotis 
rufescenes) in the primary housing unit in the 
University of Maine Aquaculture Research 
Center. 
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of the tube. The supernatant, or remaining solution above the coalesced pellet, was then 
removed and placed into a new Eppendorf tube on ice. The supernatant samples were then 
subjected to 3 hours of 15,000 g centrifugation at 4oC. This resulted in the formation of an 
opalescent blue hemocyanin pellet in the bottom of the centrifuge tube. The supernatant 
was then removed, and the hemocyanin pellet resuspended in 150 uL hemocyanin 
stabilization buffer (HSB), a solution used as reported in other studies (19). The formula 
for this solution is 50 mM Tris HCl, 5 mM CaC12, 5 mM MgC12, pH 7.4. The hemocyanin 
concentration was determined via Bicinchonic Acid (BCA) analysis using a Pierce™ BCA 
Protein Assay Kit (ThermoFisher Scientific, Catalog No. 23225). 
 Published KLH experiments use a 1.0% solution of ammonium molybdate to 
separate the one hemocyanin subunit by selectively dissociating the other (14). The intact 
subunit can then be purified through size exclusion methods, such as polyacrylamide gel 
electrophoresis (PAGE) or gel filtration chromatography (GFC). I prepared a PEG 0.2% 
Mr 1,000 solution with the pH adjusted to 5.9 at room temperature using 1 N NaOH. This 
solution is referred to as AMPEG. The dissociated hemocyanin subunit can be gathered 
and chemically re-associated. Samples were exposed to AMPEG by direct buffer exchange 
(hemocyanin pellet formation via centrifugation, supernatant removal, and administration 
of AMPEG), overnight cassette dialysis against AMPEG, and buffer exchange spin 
columns (ThermoFisher Scientific, Catalog No. 89849) (2). The marine anticoagulant, 
however, was not effective with RAH and was omitted in later experiments. 
 
Hemocyanin Purification 
 I purified hemocyanin in three different ways. First, following the KLH literature 
closely, dissolved RAH samples in AMPEG were subject to gel filtration chromatography. 
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Gel filtration chromatography was performed precisely as according to Harris et al. 1995; 
“in the presence of AMPEG solution at 4°C through Bio-Gel A-15m, 200-400 mesh 
(Biorad Laboratories). The column, 1 m in height and 15 mm diameter (bed volume 180 
cm3), was thoroughly equilibrated with the AMPEG solution, prior to the application of 
the pelleted and AMPEG-dialyzed KLH sample” (19).  Commercial protein standards 
(Biorad Laboratories) were used to calibrate the column and determine the molecular 
weight ranges of the fractions eluted. The protein concentrations and identities were 
determined via spectrophotometry. 
 All RAH samples were subjected to native and SDS denaturing PAGE (NuPAGE 
®) following the protocol included for Tris-Acetate Mini Gels (MAN0003679). RAH was 
purified from native PAGE gels through the excision and elution protocol of Tech Tip #51 
(ThermoFisher Scientific, TR0051.1). This consisted of cutting the separated hemocyanin 
protein band out of the gel, grinding it into an elution solution, and incubating it at 37oC 
overnight. The protein was then recovered from the supernatant of the centrifuged sample, 
and subject to follow-up native PAGE to determine purification efficacy. Alternatively, 
RAH samples were ‘cleaned’ by serial centrifugation in protein desalting spin columns 
with a molecular weight cut-off of 7 kDa (ThermoFisher Scientific, MAN0011469). These 
centrifuge tubes function as filters that remove particulates lighter than the given molecular 
weight cut-off. Many RAH contaminants were small, so repeated (3x) filtration with these 
units was successful in enhancing RAH purity.  
 The most efficient purification protocol utilized RAH samples that were not 
exposed to marine anticoagulant nor AMPEG. These hemocyanin pellets, dissolved in 
HSB, were subject to filtration with the desalting spin columns, repeated three times, using 
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more HSB as the exchange buffer. This procedure was inspired by and modeled after the 
similar and effective serial filtration regime of Zanjani et al. 2016 (20). The subunit sizes 
of these efficiently purified RAH samples were directly compared to those of KLH from a 
commercial KLH-hapten conjugation kit (ThermoFisher Scientific, MAN0011175) 
through the previously described native PAGE conditions. 
 
Hapten-carrier Efficacy 
 A commercially available Imject™ KLH hapten conjugation kit (ThermoFisher 
Scientific, Catalog No. PI77600) was utilized for hapten conjugation with KLH and RAH. 
This kit includes industry grade KLH for hapten conjugation in research. Other necessary 
materials were Sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate) (ThermoFisher Scientific, Catalog No.  22322), Imject Maleimide 
Conjugation Buffer (ThermoFisher Scientific, Catalog No.  77164), and 20 mg of 
sulfhydryl-containing hapten. The hapten chosen was thiosalicylic acid (Acros Organics, 
Mfr. No.138891000). Thiosalicylic acid was chosen because of its low molecular weight 
and available sulfhydryl groups.  
 The RAH samples used for conjugation were never exposed to marine 
anticoagulant nor AMPEG; the hemocyanin pellet was simply dissolved in HSB and 
filtered of contaminants through serial centrifugation with desalting spin columns 
(ThermoFisher Scientific, Catalog No. 89849). The hemocyanin concentration of these 
samples was determined using the Pierce™ BCA Protein Assay Kit (ThermoFisher 
Scientific, Catalog No. 23225). The previous methods provided insight to proper 
hemocyanin processing and led to the identification of a reliable experimental procedure. 
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 The hapten conjugation process was then repeated with control samples of 
Phosphate Buffered Saline (PBS) and no protein. Without a hapten-carrier, the thiosalicylic 
acid was removed from the sample during an excess filtration step. A substitute 20 mg of 
thiosalicylic acid was then added to the finished solution, which had been processed like 
the hemocyanin samples.  
 These samples were then sent to Pocono Rabbit Farm and Laboratory (PRFL), an 
antibody production facility in Canadensis, PA. PRFL prepared 6 mice for this study. Two 
positive control mice were injected with the KLH-thiosalicylic acid conjugate, two 
experimental mice were injected with the RAH-thiosalicylic acid conjugate, and two 
negative control mice were injected with the PBS-thiosalicylic solution. PRFL uses a 
proprietary antibody production regime called the Mighty Quick Protocol to raise mouse 
antibodies in 28 days. This is an accelerated process using a proprietary immune-stimulant 
(Mighty Quick Stimulant). PRFL is a KLH consumer; they use KLH predominately for 
their experiments. Therefore, Mighty Quick Stimulant is not anticipated to interfere with 
hemocyanin immune modulation.  
 Antibody production began on April 9th, 2018, when PFRAL injected the six mice 
with the respective samples; two with KLH conjugated hapten, two with RAH conjugated 
hapten, and two with the hapten in a PBS solution. Serum samples were extracted, and 
ELISA was performed after the 28-day incubation period to quantify antibody production. 
ELISA measures antibody production by determining the maximum dilution of the sera 
that reacts to the antigen. Titers are the dilutions of the mouse sera that react to the given 
antigen. PRFL measures titers by performing an initial dilution of the mouse sera at 1:300, 
and then in three-fold (1:3) dilutions across 11 wells on a 96 well microtiter plate. The titer 
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steps, or dilution factors, are referred to as the reciprocal of the dilution (i.e. 300, 2,700, 
8,100, etc.). The antibody response was measured only for the hapten, thiosalicylic acid, 
as that was the molecule I was attempting to vaccinate against. The antibody response to 
the hapten carrier itself should be minimal; effective vaccine stimulates a response to the 
desired antigen, in this case thiosalicylic acid, not the carriers. ELISA was therefore 
performed using the RAH-thiosalicylic acid conjugate solution with the KLH-thiosalicylic 
conjugate injected mice and vice versa; one hemocyanin-hapten solution was used as the 
antigen for ELISA of the other hemocyanin. This isolates the results to the immune 
response generated solely against the hapten because antibodies produced against KLH 
will not react to RAH and vice versa. If RAH is a competitive hapten-carrier alternative for 
vaccine production, RAH-thiosalicylic acid conjugated samples and as KLH-thiosalicylic 
acid conjugated samples should elicit a similar antibody production, measured with titers, 
against thiosalicylic acid in mice. Both samples should theoretically result in far greater 
antibody production than the PBS-thiosalicylic acid solution, which does not have a way 
to present the small dissolved haptens to the immune system. This control was used as the 
antigen for control mouse sera; the PBS-hapten solution measures the immune response 
against the hapten alone. The results of ELISA testing will indicate if RAH can be used 
instead of KLH in a variety of immunology applications. 
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RESULTS 
 
 
 
Abalone Aquaculture 
 Seventeen of the total 42 abalone experienced mortality during this study. Five 
abalone succumbed to heat-stress during separate instances of temperature regulation 
malfunctions. All abalone were temporarily moved to several smaller enclosures for two 
weeks during system repairs in 2016. Seven abalone escaped these temporary enclosures 
and desiccated in the facility. The water quality, temperature, salinity, and light parameters 
of the primary and temporary housing were identical. The major difference was that the 
abalone were split into three groups housed in smaller circular tanks. All enclosures were 
open, as abalone had not been observed to escape before. It is unclear why the abalone left 
these aquaria, but none ever escaped from the circular-topped original tank through the 
entire study. The cause of death is unknown for five abalone that were found deceased in 
the enclosure during this study. None of the bled abalone experienced mortality.  
 The behavior of bled abalones was normal compared to that of wild and aquaculture 
animals. Abalone were nocturnal, active when hungry, and perceptive of motion in and 
around the tank. Their typical defensive posture is to withdraw into their shell and fasten 
themselves to the wall of the tank; the general vitality of an individual can be gauged by 
the vigor with which it can hold onto the tank wall. The health of seemingly lethargic 
abalone was routinely assessed via this method. The abalone exhibited a gradient of space 
utilization; many abalone would typically crowd one side of the tank while fewer were 
further away.  
 Abalones rapidly produce fecal matter, and excess food partially dissolves, 
necessitating consistent cleaning and vigilance. All abalones grew through the course of 
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the study. Nutrients from abalone feed are incorporated into the shell, and shell color is 
influenced by feed composition. The 2016 switch in feed resulted in a change of new shell 
growth color. Variations in water quality (i.e. a temperature increase to over 17OC or a 
nitrate concentration above 0.5 ppm) were rare and addressed immediately. Most abalone 
mortality was attributed to system malfunctions and escapes. This general aquaculture 
regime was therefore successful for 4 years of abalone maintenance. Abalone maintenance 
required 4 hours of direct care per week. 
 
Hemolymph Extraction 
 The extraction of hemolymph was a skill honed and refined throughout this study. 
The hemolymph extraction protocol was reliable, but finding the pedal sinus is far more 
difficult in practice than in theory. The dimensions of each abalone are different, and the 
contour of muscles and viscera in this invertebrate continuously stretch, contract, or 
otherwise change the shape of the pedal sinus. If the needle is too shallow or too deep it 
will be buried in tissue and no hemolymph will be drawn. Once the needle is properly in 
the pedal sinus, however, hemolymph flows readily into the syringe. By the end of the 
study the pedal sinus could be found quickly, and the number of necessary punctures were 
greatly reduced. The four abalone that were bled during two experimental sessions had four 
months to recuperate between sessions. 
 
Hemocyanin Isolation 
 The two-phase centrifuge regime of producing a cell-free supernatant, then a 
predominately hemocyanin pellet, was consistently successful. Abalone hemocyanin 
accounts for 90% of total hemolymph proteins (2). The hemocyanin subunits of other 
 18 
 
abalone species are known to have a molecular weight of at least 350 kDa, which is 
significantly heavier than most other hemolymph components (2). Hemocyanin, therefore, 
pellets out of suspension before most other hemolymph components. Despite this, a 
minimum of 2.5 hours in the centrifuge at 15,000 g was required to start pelleting 
hemocyanin. The hemocyanin pellet is visually distinguishable by its opalescent blue color. 
The mass of the pellet was not determined. BCA analysis at this point in the purification 
process consistently reflected a hemocyanin concentration of approximately 3 mg/mL 
(Table 2).  
 AMPEG was designed to prepare KLH subunits for size exclusion purification 
methods such as polyacrylamide gel electrophoresis (PAGE) or gel filtration 
chromatography. This buffer selectively dissociates only one of the two hemocyanin 
subunits. The subunits are similar in size–one is approximately 350 kDa while the other is 
approximately 400 kDa. These subunits could not, therefore, be separated from each other 
by size exclusion purification methods without this step. AMPEG, however, has been 
known to occasionally denature all hemocyanin in solution and cause precipitate formation 
(11). This is usually triggered by temperature variation or excess agitation of the sample 
(11). All RAH samples prepared with AMPEG exhibited protein denaturation and 
precipitate formation; the solutions turned cloudy gray and fine white particulates formed. 
This reaction occurred when AMPEG was introduced via direct buffer exchange, overnight 
cassette dialysis, and buffer exchange spin columns. This may be an inherent reaction 
between AMPEG and RAH, or there may have been a handling issue with the introduction 
of this buffer.  
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 The marine anticoagulant was a precautionary measure to prevent hemolymph from 
clotting against bacterial exposure in the hemolymph. Once the process of RAH 
purification was refined using the marine anticoagulant in the original sample Eppendorf 
tubes, the procedure was replicated omitting the marine anticoagulant. The same results 
were achieved, and the marine anticoagulant was deemed unnecessary.  
 
 
 
Figure 3. Shows the standard curve generated 
for BCA analysis. Bicinchonic Acid (BCA) 
analysis was performed using a Pierce™ BCA 
Protein Assay Kit (ThermoFisher Scientific, 
Catalog No. 23225). 
 
 
 
 
Table 1. Shows the protein concentration 
determined via BCA of 6 representative 
hemocyanin samples (SPL1-SPL6). These 
were typical results when the hemocyanin 
concentration was measured after the RAH 
isolation protocol. The concentration was 
determined by the standard curve 
generated for BCA analysis; the 
spectrophotometric absorbance at 562 nm. 
Bicinchonic Acid (BCA) was incorporated 
into the equation y = 1.1551x - 0.0154 for 
the variable ‘x’. The hemocyanin 
concentration of H. rufescenes hemolymph 
is thus approximately 3 mg/mL. 
 
 
 
 
 
 
Hemocyanin Purification 
 The gel slurry used to prepare the gel filtration chromatography column took nearly 
six hours to ‘pack’ or settle, yet exhibited inconsistent compaction. Slight temperature 
Well 
ID A562 Count Mean 
Concentration 
(mg/mL) 
PL1 2.088 2 2.123 2.436877 
  2.157      
SPL2 2.889 2 2.87 3.299737 
  2.851      
SPL3 2.299 2 2.341 2.688689 
  2.384      
SPL4 2.863 2 2.812 3.232741 
  2.761      
SPL5 2.407 2 2.382 2.736048 
  2.357      
SPL6 2.958 2 2.981 3.427953 
  3.005      
y = 1.1551x - 0.0154
R² = 0.9977
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variations resulted in changes to the density of the slurry, interrupting the experiment.  
Bubbles often formed before the gel was caste, which interfere with the filtration. 
Stabilizing the flow rate through the column was consistently challenging, even when using 
a peristaltic pump. This original protocol included casting and calibrating the column in 
AMPEG, which was found to later interfere with the spectrophotometry. This interference 
was reported by other KLH researchers. Gel filtration chromatography was therefore 
eliminated as a viable means of RAH purification.  
 Native and SDS denaturing PAGE were successful for determining the subunit 
composition and molecular weight of RAH. RAH was the most prevalent protein in the 
samples, though consistent contaminants persisted prior to purification. The two RAH 
subunits were identified as being nearly identical in molecular weight, both at 
approximately 375 kDa. Often the protein bands of these subunits would appear as a single 
smudged band, but in rare cases the subunits were separated (Figure 5 and Figure 7). These 
samples were prepared the same way, so it is unclear what caused the subunit separation. 
Gel images showing the RAH subunits and contaminants are shown in Figures 4-7. The 
approximately 800 kDa protein band was suspected to be aggregates of RAH subunits, as 
a similar configuration is found in KLH research. Gel excision and protein elution of the 
375 kDa and 800 kDa protein bands resulted in the concentration and isolation of 375 kDa 
protein with relatively little contaminates via PAGE. This shows that the 800 kDa protein 
band was indeed aggregated hemocyanin subunits. RAH samples that were ‘cleaned’ via 
serial centrifugal filtration with desalting spin columns were consistently purified from 
most contaminants. PAGE results of these samples clearly show RAH to be composed of 
two approximately 375 kDa subunits. The remaining contaminants were consistent through 
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all samples, though less concentrated. In one instance the eluted protein sample from 
excised 375 kDa and 800 kDa bands was subjected to the ‘cleaning’ process, resulting in 
the most purified sample of the study.  
 Commercial KLH from the Imject™ kit was compared to the most efficiently 
‘cleaned’ RAH samples on one native PAGE gel (Figure 6). The resulting gel showed the 
two KLH subunits were separated in size by about 50 kDa, while the two RAH subunits 
were closer in molecular weight. Both RAH subunits were intermediate to the size range 
of the two KLH subunits. Both KLH subunits function as effective hapten-carriers, 
meaning the RAH subunits are in the proper size range for an alternative hapten-carrier. 
Both experimental RAH and commercial KLH contained the same contaminants, in similar 
concentrations. This gel is shown in Figure 6. This RAH purification rivals industry grade 
KLH purification for hapten conjugation. 
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  Figure 4. Native PAGE of RAH samples. Lanes–  
1: Crude RAH.  2: ‘cleaned’ RAH. 3: molecular 
weight markers (RAH is between 480 kDa and 242 
kDa). 
 4-7: ‘cleaned’ RAH in decreasing concentrations. 
Figure 5.  SDS denaturing PAGE of RAH and KLH 
samples. Lanes– 1,2,3,4,6,7,9,10: ‘cleaned’ RAH 
after one cycle of filtration via desalting spin 
columns. Samples become more purified after three 
cycles. 5: molecular weight markers (RAH is just 
below 400 kDa). 8: crude (uncprocessed) 
hemocyanin (raw hemolymph). Clear separation of 
two RAH subunits are shown in wells 9 and 10. 
Figure 7. Native PAGE of RAH samples. Lanes– 1, 
3, 4: ‘cleaned’ RAH. 2, 6, 7: excised and eluted 
RAH. 5: molecular weight markers (RAH is 
between 480 kDa and 242 kDa). 8-10: crude 
(unprocessed) hemocyanin (raw hemolymph). 
Smudged separation of two RAH subunits are 
shown in wells 8 and 10. 
Figure 6.  Native PAGE of RAH and KLH 
samples. Lanes– 1,c,d,e: KLH (Commercial hapten 
carrier). 2-9,a,b: ‘cleaned’ RAH. Both RAH 
subunits are between KLH subunits in size. 
Commercial KLH and experimental RAH have 
similar impurities.  
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Hapten-carrier Efficacy 
 Thiosalicylic acid was conjugated to KLH and RAH respectively using the 
Imject™ conjugation kit. Control samples of thiosalicylic acid in PBS were prepared in the 
same way as the protein samples and ensured to contain the hapten. These solutions were 
successfully shipped to PFRAL. PFRAL performed a BCA assay on the samples prior to 
beginning their analysis, to confirm their protein concentration. The KLH sample was 
expected to have a concentration of 3.9 mg/mL and was found to have a concentration of 
3.6 mg/mL. The RAH sample was expected to have a concentration of 1.3 mg/mL and was 
found to have a concentration of 1.25 mg/mL. The conjugation process had high efficiency.  
 Sera was collected from all six mice at days 0 (prior to injection to establish a 
baseline of inherent antibody production against the hapten), 21, and 28 of the incubation 
period. PFRAL identified the day-28 samples as being the most accurate gauge of antibody 
production. Therefore, only day-28 ELISA results are reported. Sera was tested using the 
other hemocyanin-hapten conjugated solution as the antigen, i.e. ELISA was performed on 
KLH-thiosalicylic acid conjugate injected mouse sera using RAH-thiosalicylic acid 
solution and vice versa. The titer steps were determined by diluting the sera 1:300 in PBS. 
Serial threefold dilutions of this solution are used to create establish the titers (300, 2,700, 
8,100… 1,986,000). The maximum titer (dilution factor) of the sera that reacts to the 
antigen is a measure of antibody production. These titers are compared as ranked ‘steps’ 
(i.e. the first titer of 1:300 is the ‘1st titer step’, while a titer of 24,300 is the ‘5th titer step’). 
Each ‘titer step’ represents a geometric threefold difference; three ‘titer steps’ is a 27-fold 
difference and so on. 
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 Serum samples were collected from all six mice on May 11th. Sera was shipped on 
ice to the University of Maine and has been stored for potential future analysis. The hapten-
carrier solutions were prepared at different concentrations but were standardized for the 
hemocyanin mass in each by PFRAL. A 200 ug injection of hapten-carrier solution was 
administered on day 1 of incubation (this first ‘day’ beginning at the moment of injection), 
and 100 ug injections were administered intermittently through the study through the 
consistent PFRAL procedure. All injections were prepared to have a concentration of 
approximately 1 mg/mL. The KLH-thiosalicylic conjugated solution originally had a 
concentration of 3.5 mg/mL. 0.057 mL and 0.029 mL of this sample were mixed with 0.15 
mL of adjuvant and brought to a volume of 0.25 mL per animal with PBS, respectively for 
the 200 ug and 100 ug injections. The RAH-thiosalicylic conjugated solution originally 
had a concentration of 1 mg/mL. 0.2 mL and 0.1 mL of this sample were mixed with 0.15 
mL of adjuvant and brought to a volume of 0.25 mL per animal with PBS, respectively for 
the 200 ug and 100 ug injections. The control solution of thiosalicylic acid in PBS had an 
original hapten concentration of 2mg/mL. 0.1 mL and 0.05 mL of this sample were mixed 
with 0.15 mL of adjuvant and brought to a volume of 0.25 mL per animal with PBS, 
respectively for the 200 ug and 100 ug injections. Antibody production was assessed via 
an ELISA procedure performed in duplicate for each dilution and included a no-antibody 
control to ensure the absence of an independently reactive agent in the antigen solution. 
 The first KLH-thiosalicylic acid conjugate treated mouse reacted until the 9th titer, 
a dilution of 1:1,968,300. The second KLH-thiosalicylic acid conjugate treated mouse 
reacted until the 8th titer, a dilution of 1:656,100. The first RAH-thiosalicylic acid conjugate 
treated mouse reacted until the 6th titer, a dilution of 1:72,000. The second RAH-
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thiosalicylic acid conjugate treated mouse reacted until the 5th titer, a dilution of 1:24,300. 
No reaction occurred for any dilution of the PBS-thiosalicylic acid treated mice sera. The 
shows that KLH is potently immunogenic, RAH is moderately immunogenic, and 
thiosalicylic acid without a carrier is not immunogenic. This analysis was for ‘proof-of-
concept’ and the study was not designed large enough to be statistically sound. Methods of 
statistical analysis were therefore not performed; only preliminary trends were observed. 
The ELISA results are shown in Figure 8. 
 
 
Figure 8. Shows the antibody response, in titer dilutions, to thiosalicylic for the KLH, RAH, and 
PBS carrier-treated mice. The antibody titers produced in two KLH-hapten treated mice were 
1,968,000 and 656,000, 9 and 8 dilutions respectively. The antibody titers produced in two RAH-
hapten treated mice were 72,000 and 24,000, 6 and 5 dilutions respectively. No antibodies were 
produced against thiosalicylic acid in both PBS-hapten treated mice. 
  
300
2700
24300
218700
1968300
Mouse 1 Mouse 2 Mouse 1 Mouse 2 Mouse 1 Mouse 2
KLH RAH ControlAn
tib
od
y 
Pr
od
uc
tio
n 
Ti
tie
rs
 (r
ec
ip
ro
ca
l 
of
 se
ra
 e
nd
po
in
t d
ilu
tio
n 
du
rin
g 
EL
IS
A)
Antibody Production against Thiosalicylic Acid in 
Mice Using Hemocyanin Hapten Carriers
 26 
 
DISCUSSION 
 
 
 
 Abalone maintenance at ARC provided insight to strategies and issues for their 
aquaculture. The general protocol was successful; water quality, temperature, salinity, flow 
rate, and enclosure lighting were conducive to abalone health and growth. These 
parameters were consistent through most of the study, with few deviations due to system 
malfunctions or reconfigurations. The mortality of abalone due to heat shock shows that 
the upper thermal tolerance of this species is 17oC. Exposure to this warmer water resulted 
in mortality after 2 days in each instance. Therefore, a commercial abalone production 
facility must maintain water temperature below 17oC and have contingency plans to cool 
the water quickly in emergency situations.  
 No abalone escaped from the open-topped original tank, nor were any observed 
above the water-line. The seven abalone that escaped the temporary housing exhibited no 
erratic behavior prior to their escape. All seven escapees left their tanks in a period of 4 
days. No abnormal water quality, temperature, salinity, or other parameters were observed 
for that period. Abalone hatchery protocols suggest that abalone prefer tanks with corners 
and straight sides, as supported by experimental observations (21). Netting was used over 
these temporary tanks after the 4 days of escape to eliminate the possibility of further loss. 
Netting was also used when the abalone were returned to the original tank, but was removed 
when no abalone was observed above the water-line for two weeks. 
 The five abalone that died of unknown causes were always the smallest (in shell 
length) of the group. There is a possibility that they were out-competed for food, but some 
of the bodies displayed symptoms of Withering Foot Syndrome (WFS). This disease is 
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caused by the bacterium Candidatus xenohaliotis californiensis, which infects the abalone 
digestive tract and inhibits digestion enzyme production (22). The body mass of the 
abalone rapidly diminishes as it starves (22). Observed symptoms included this shrinking 
of abalone foot and mantle size. WFS is a global problem for abalone harvest in the wild 
and aquaculture, and especially common in California (22). The abalone most likely were 
infected with WFS before arrival at ARC. 
 Most abalone losses were clearly attributed to maintenance issues, and the 
remaining losses were likely natural or caused by a common industry pathogen. General 
parameters such as 35-38 ppt salinity, 12OC water, and thresholds for molecules such as 
ammonia, nitrite, and nitrate were established for long-term abalone maintenance.  This is 
an important result, showing that abalone maintenance is feasible in recirculating 
aquaculture settings. Abalone farms are typically coastal and use seawater directly from 
the local environment. Sea water is pumped directly into these facilities, then returned to 
the environment. This is a high-risk process; toxic algae, pollution, diseases, and parasites 
are often introduced to farmed abalone via the natural sea water. The global abalone 
farming industry struggles with sometimes catastrophic crop losses due to wild diseases, 
like WFS and parasites such as shell-boring annelids, introduced through the natural sea 
water (21). Recirculating aquaculture allows the producer to have more control of what is 
or is not in the water. Abalone raised in recirculating conditions are thus safer, and the 
process is more stable. This study shows that abalone can be housed in long-term 
recirculating conditions, with artificial sea water. Assessing the efficacy of recirculating 
aquaculture maintenance is critical to the development of an abalone farm in Maine, 
because abalone cannot be exposed to natural waters in this state. As a foreign species from 
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the Pacific, it is illegal to allow abalone any means of escape, whether larval or adult, into 
Maine waterways. These abalone, and any diseases or parasites they carry, may become 
invasive species if released in Maine, damaging the local ecosystem. An abalone farm in 
the state would therefore be responsible for preparing and disposing its own artificial sea 
water in a way that does not introduce abalone material to the natural environment. 
 Hemolymph extraction was initially challenging, though refined into a skill through 
this study. Locating the pedal sinus on an abalone diagram and a live specimen are different 
endeavors. The ice-bath method of cooling the abalone prior to hemolymph extraction was 
essential to successful hemolymph extraction. It is nearly impossible to extract hemolymph 
from a moving specimen. None of the abalone bled through the study died or displayed 
adverse health effects. 2 mL of hemolymph is therefore a ‘safe’ volume for extraction; this 
process is not anticipated to kill or harm a healthy abalone.  
 The hemocyanin-isolation process was modeled directly from KLH literature. The 
initial 30-minute 800 g 4oC centrifugation was consistent in the literature and shown to 
effectively remove whole cells and large debris from the sample. The second centrifugation 
step, however, was experimentally refined. The first samples of this study were centrifuged 
at 15,000 g and 4oC for 30-minute intervals. At the end of each interval the samples were 
checked for the formation of a visible hemocyanin pellet. The pellets consistently formed 
after 2.5 hours at this speed, but were visibly larger after an additional interval. 3 hours was 
therefore determined to be the standard centrifugation time for hemocyanin pellet 
formation in subsequent experimentation.  
 The hemocyanin concentration after centrifugal isolation and resuspension in HSB 
was approximately 3 mg/mL (Table 2). The normal hemocyanin concentration in red 
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abalone hemolymph is thus approximately 3 mg/mL. The KLH concentration of M. 
crenulata hemolymph is also approximately 3 mg/mL. This is the first experimental 
similarity between RAH and KLH: the concentration of each protein is the same in the 
hemolymph of the respective species. Theoretically, therefore, the same amount of RAH 
and KLH can be produced from equal hemolymph volumes from each species. 
 Removing the marine anticoagulant from the refined protocol had no negative 
effect on the final RAH purity. Use of the marine anticoagulant was therefore discontinued. 
Abalone exhibit a slow clotting process, and therefore an anticoagulant is not necessary.  
 I could not adequately configure gel filtration chromatography to purify the RAH. 
Methods were designed from Harris et al. 1995 and followed carefully (19). The gel slurry 
would settle inconsistently and change density during column calibration, despite using the 
recommended materials. Issues with column preparation, such as bubble formation, remain 
mysterious. Various methods of troubleshooting, including changing the experimental 
temperature of the column and mobile phase and the use of a pump to control the flow rate, 
were unsuccessful in standardizing successful column setup. Control proteins of known 
molecular weight could not be consistently recorded.  
 Some RAH samples were exposed to AMPEG prior to GFC so that one subunit 
could be separated from the other. AMPEG, however, interferes with spectrophotometer 
function, preventing protein identification and analysis. This problem was reported by 
other KLH researchers, who had to use more complex means of hemocyanin identification 
after GFC elution (11). These issues suggest that neither AMPEG nor GFC are useful in 
RAH purification. 
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 Native and SDS PAGE of crude (unprocessed) H. rufescenes hemolymph confirms 
that RAH is the most abundant hemolymph component. Serial centrifugation of isolated 
RAH successfully removed most contaminants, and drastically reduced the concentration 
of others. This ‘purified’ RAH was shown to be composed of two subunits, approximately 
375 kDa each. Sometimes the subunits appeared as a single smudge, and other times there 
was clear separation. This occurred in samples prepared and handled the same way, so it is 
unclear what caused the occasional separation, which was observed in native and 
denaturing settings. 
 KLH is also known to be composed of two subunits. One subunit is approximately 
350 kDa, while the other is approximately 400 kDa. Industry grade KLH for hapten-
carrying uses a mixture of both hemocyanin subunits. The emerging vaccines typically 
utilize only one subunit, but both are effective. There is no biochemical need to isolate one 
subunit for vaccine production, especially since KLH aggregates are typically sorted by 
subunit (2). RAH is therefore within the molecular weight range of KLH formulations for 
hapten-carrying and vaccine production.  
 ‘Purified’ RAH was directly compared to a commercial formulation of KLH 
hapten-carrier via native PAGE. The results show that both RAH subunits are between the 
two KLH subunits in molecular weight. This suggests that both RAH subunits are viable 
alternative hapten-carriers, alone or together. The commercial KLH and experimental RAH 
were shown to have similar contaminants. The non-hemocyanin protein bands match from 
both types of samples. The RAH purification protocol therefore succeeded in producing 
RAH that rivals commercial KLH in purity. 
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 The PFRAL assessment of antibody production via ELISA shows that RAH is a 
viable hapten carrier. A solution of thiosalicylic acid in PBS was administered to mice as 
a negative control. No antibodies whatsoever were raised against thiosalicylic acid in these 
mice. Thiosalicylic acid is therefore a proper hapten, it is too small to elicit an immune 
response. Mice treated with the RAH-thiosalicylic acid conjugate, however, exhibited 
antibody production of 5 to 6 titers. This was described as a moderate antibody response 
by scientists at PFRAL. The KLH-thiosalicylic acid conjugate treated mice exhibited the 
greatest antibody production in this study. The titers for KLH-treated animals were 2 to 3 
titers higher than the RAH-treated animals, a 9 to 27-fold difference, respectively. KLH is 
therefore more potent than RAH as a hapten carrier. For immunological applications, 
however, RAH may still be useful. The supervisor for this project at PFRAL explained that 
while RAH did not perform at the same level as the KLH, it did provoke a reasonable 
immune response. This scientist elaborated that if the present results are corroborated with 
a more statistically sound study using an industry standard hapten, RAH would be a 
suitable alternative to KLH for antibody production. 
 It is possible that the similarity of sizes between the RAH subunits contributed to 
the lesser hapten carrier efficacy compared to KLH. KLH subunits are ~350 kDa and ~400 
kDa, there is a ~50 kDa difference between their sizes. RAH subunits were found to both 
be ~375 kDa. The KLH subunits aggregate either in groups of just KLH1, or predominately 
KLH2 with some KLH1 present (14). The less distinct RAH subunits may all aggregate 
together, leaving less surface area available for hapten conjugation than that of the two 
aggregate assemblies of KLH. This can be tested through the identification and 
implementation of a selective dissociation buffer for one of the RAH subunits, as has been 
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developed for KLH. It is also possible that in some commercial applications, a moderately 
immune-stimulating molecule may be preferable to one of the strongest known immune-
stimulating molecules. RAH is therefore immunogenic enough to be a viable alternative 
hapten carrier, but also can be used for other purposes that KLH is too potent for.  
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CONCLUSION 
 
 
 
 Sustained H. rufescenes maintenance is feasible in recirculating aquaculture. 
Netting or a cover is recommended for abalone housing. Heat stress begins at 
approximately 17oC in H. rufescenes and can be fatal within 48 hours. Response protocols 
to temperature variation are therefore critical to responsible abalone maintenance. 
Hemolymph extraction of 2 mL does not negatively impact overt abalone health. 
Hemocyanin concentration in H. rufescenes hemolymph is approximately 3 mg/mL, the 
same as in M. crenulata hemolymph. Successful protocols for RAH isolation and 
purification were created through this study. Serial centrifugation of isolated RAH with 
desalting spin columns removes most contaminants after three cycles. This processed RAH 
rivals commercial KLH in purity. RAH was found to be composed of two subunits, each 
approximately 375 kDa. KLH is also composed of two subunits, 350 kDa and 400 kDa 
respectively. Both KLH subunits are trusted hapten-carriers, and a mixture is often used in 
immunology applications. RAH therefore has the proper structure and molecular weight to 
be a competitive substitute to KLH. Hapten conjugation to both hemocyanin types shows 
that RAH is an effective hapten carrier. RAH successfully initiated a moderate immune 
response to a hapten that was otherwise non-immunogenic. Industry evaluation considers 
the RAH-mediated immune response to be suitable for use as an alternative hapten carrier 
to KLH. The KLH-mediated immune response was 2 to 3 titers greater than that of RAH. 
The less potent immune reaction to RAH may be useful in commercial circumstances. The 
viability of abalone maintenance in recirculating aquaculture, development of successful 
RAH processing techniques, and comparable biochemical characteristics suggest that RAH 
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may be a successful alternative hapten-carrier to KLH in vaccine production. The global 
aquaculture of H. rufescenes is an additional advantage to RAH production. 
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FUTURE DIRECTIONS 
 
 
 
 Maine is the ‘seafood state’ and excels in aquaculture. The Maine seafood market 
has a history of successfully introducing new food products to the East Coast, then 
throughout the United States. A major expense for abalone farms is feed; abalone eat 
seaweed and algae. Maine is a leading East Coast state in seaweed aquaculture and wild 
harvest. Partnership with local seaweed producers provides a unique opportunity for 
reducing the cost of abalone feed in Maine. There is precedent and interest for abalone 
aquaculture in Maine; the Maine Technology Institute awarded $17,000 to a start-up 
abalone farm in 2012 (22). Dominant New Zealand abalone farms were concerned that 
abalone aquaculture would be successful in the state and recruited the leading entrepreneur 
from the MTI grant to New Zealand, preventing development in Maine. The CEO of 
Campbell Science, an abalone beta-gulcuronidase distributor, laments that there are no 
abalone farms capitalizing on biomedical products, adding that the East Coast would be an 
ideal market location. Other abalone products, such as meat and pearls, would enable 
consistent profitability while RAH undergoes approval for immunology and vaccine 
applications. Business incubation space was secured at the Mount Desert Island Biological 
Laboratory in 2018 for the development of an abalone farm in Maine. Business and 
scientific developments are advancing rapidly. The mission of this company is to 
sustainably develop biomedical products from marine invertebrates while utilizing the 
entire organism to maximize market diversity and minimize waste. 
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Appendix A: KLH and Abalone Hemocyanin Biochemistry 
Hemocyanin, stemming from the Greek ‘haima’ meaning blood, and ‘kyanus’ 
meaning blue pigment, is a respiratory protein found commonly in invertebrates (8). This 
large glyco-metallaprotein, discovered by French naturalist Leon Fredriq in 1878, is 
responsible for the transportation of oxygen molecules through arthropods and mollusks 
(8). There are typically 7 or 8 oxygen binding sites on the protein, dubbed functional units, 
where binuclear copper is bound to a branching side chain of amino acids and readily binds 
with oxygen molecules brought in by the respiratory system (23). The oxygenated copper 
has a light absorbance near 340 nanometers, causing the rich opalescent blue color of 
mollusk blood, or hemolymph (24). Dull grey samples of hemolymph indicate denatured 
proteins (2). The Functional Units are referred to as ‘functional unit a-h’, depending on the 
hemocyanin type (23). In KLH the functional units are made up of dimeric morphological 
units, with individual molecular masses of 45-65 kDa, and themselves make up three-tiered 
decameric subunits of the protein (24).  These subunits comprise hollow cylindrical 
oligomers with molecular masses of 350 to 450 kDa and external diameters of 3.7 
nanometers (25). Two or more of these decamer structures have the propensity to aggregate 
and adjoin “face to face with the collar complexes at each end” to form didecamers and 
multididecamers (26). This is the native form of hemocyanin (26). The didecamers of 
gastropod hemocyanin can have total height of 40 nanometers and a mass of 7.5 to 8 MDa 
(24). Molluscan hemocyanins are the largest oxygen-carrying proteins in the animal 
kingdom (4). Hemocyanin production in gastropods is influenced by organism strength and 
stress, as well as water temperature, pH, cations, O2, calcium and magnesium (27).  
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A complete KLH didecamer is comprised of two isomorphic decamer subunits, 
dubbed KLH1 and KLH2 (25). These subunits are 60% identical at the protein level (23). 
Both KLH1 and KLH2 have 8 distinct Functional Units, each replicated 20 times through 
the manifolds of the decamer (24).  KLH1 has a molecular mass of 390 kDa, whereas 
KLH2 has a molecular mass of 360 kDa (25). Recent studies suggest that captive Keyhole 
Limpets have drastically reduced KLH1 concentrations, and some individuals lack KLH1 
altogether (26).  In most aquaculture circumstances, KLH1 and KLH2 exist in a 1:2 ratio 
within each individual Keyhole Limpet (26). 
Mannose, galactose, N-acetylglucosamine and N-acetylgalactosamine were shown 
to be present in KLH1 by gas liquid chromatography (16). Fucose was also detected in 
KLH2 (16). Both KLH1 and KLH2 are 4% carbohydrate by mass (16). This unique 
carbohydrate composition contributes to the immune-stimulating power of KLH (2). 
 Conveniently, KLH2 dissociates into its functional units in an environment of pH 
of 5.7 to pH 5.9 (14). KLH1, however, stays intact in these acidic solutions (26). This 
allows for the separation of KLH1 from KLH2 with size exclusion methods (26). The 
KLH1 can be extracted and the remaining KLH2 can be re-associated by increasing the 
solution pH (26). The source of KLH biosynthesis has not yet been identified. Little 
genomic work on M. crenulata has been conducted. Recent interest in molluscan 
hemocyanin has begun to produce research on abalone hemocyanin as well (4). 
Hemocyanin from abalone species such as Haliotis tuberculata, Haliotis rubra, and 
Haliotis diversicolor have been studied extensively in recent years (4). These hemocyanins 
are known to be produced by pore cells and some have been genomically sequenced (28, 
29). These hemocyanins are also composed of two subunits, both approximately 390 kDa 
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(2). Hemocyanin from these abalone species have similar carbohydrate composition to 
KLH (4). H. tuberculata hemocyanin has been shown to have comparable structural 
integrity to KLH but does not dissociate as well in reduced pH environments (14). This 
abalone hemocyanin is therefore considered more stable than KLH in dissociating 
conditions (14). 
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Appendix B: Comparative Fishery Considerations 
The giant keyhole limpet has a narrow population range, from the coastlines of 
northern Mexico to northern California (30). Wild populations have been overfished for 
KLH production (31). Giant keyhole limpet aquaculture is limited to one company (12). 
Most techniques and innovations for giant keyhole limpet aquaculture are proprietary (12). 
Giant keyhole limpets are omnivorous and require a more protein-rich diet than other 
marine gastropods (30). Aquaculture feed for the giant keyhole limpet is therefore more 
expensive to produce than plant-based feeds. 
The red abalone has a large population distribution, from the coastlines of southern 
Mexico to northern Canada (31). Wild populations are stable, and commercial aquaculture 
has maintained continuously lucrative production (31). There are many companies that 
aquaculture red abalone, yet the techniques and innovations for this process are accessible 
to new businesses (32). Red abalone are herbivorous, and their feed is relatively cheap (32). 
Red abalone is therefore a more ecologically sustainable and economically sensible 
aquaculture species than the giant keyhole limpet. 
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Appendix C: Market Evaluation of Limpet and Abalone Products 
 Red abalone aquaculture is globally established and successful (33). Abalone meat 
is a delicacy in many parts of the world (34). Approximately 250 tons of red abalone are 
produced in the United states per year, predominately from California and Hawaii (30). 
This annual production is valued to exceed $2 million (33). Red abalone is particularly 
profitable in the seafood industry, with a typical market price of $70/kg (33). Abalone 
shells are also prized for the gemstone ‘Mother-of-Pearl’ (12). This unique form of nacre 
is valued in fashion, design, and artisan products (34). Aquacultured red abalone can be 
induced to form horn-shaped pearls, with the same distinct iridescent blue and green pattern 
(34). These pearls often sell for more than $400 each (34). These shells and other aspects 
of abalone biology are considered to have great biotechnological value. 
 Abalone shells are also coveted by structural scientists studying material strength 
(35). MIT and DARPA study abalone shells for inspiration and emulation in new ceramics 
(36). Abalone entrails are the primary source of beta-glucuronidase, an enzyme used in 
toxicology and drug testing. This commercially important abalone biotechnology is valued 
at $20/mL. Abalone hemocyanin has also been found to exhibit anti-viral qualities, 
prompting its use in emerging herpes medications (37). Preliminary research shows that 
abalone hemocyanin mitigates herpes proliferation, offering a new approach to patient 
treatment. Limpets, including M. crenulata, have no commercial value beyond KLH (4). 
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